pyrroles has been researched along with apricoxib in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Y; Kastrissios, H; Kawabata, K; Moberly, J; Rohatagi, S; Salazar, D; Takahashi, M; Truitt, K; Wada, R | 1 |
| Hirota, T; Ikeda, T; Inoue, S; Kawai, K; Koyama, K; Oitate, M | 1 |
| Breese, T; Dale, JC; Harris, SI; Lawson, J; McLaughlin, P; Moberly, JB; Riff, DS; Truitt, KE; Wan, Y; Xu, J | 1 |
| Gao, Y; Kastrissios, H; Moberly, J; Rohatagi, S; Salazar, D; Takahashi, M; Truitt, K; Wada, R; Xu, J; Yoshihara, K; Zhang, N | 1 |
| DiGiovanni, J; Franco, E; Fujiwara, K; Hanai, M; Kawamoto, T; Kiguchi, K; Kurakata, S; Ruffino, L; Rumi, M | 1 |
| Bandy, DP; Daniels, SE; Desjardins, PJ; Lawson, JE; Link, AJ; Moberly, JB; Truitt, KE; Xu, J | 1 |
| Ham, M; Kaunitz, JD | 1 |
| Inoue, S; Kawara, A; Kimura, T; Kumakura, S; Murakami, Y; Nakao, A; Suzuki, K; Ushiyama, S; Yamada, T | 1 |
| Fujiwara, K; Hanai, M; Inoue, S; Ishida, S; Kimura, T; Kurakata, S; Senzaki, M; Yada, A | 1 |
| Kastrissios, H; Moberly, JB; Rohatagi, S; Salazar, DE; Sasahara, K; Truitt, K; Wada, R | 1 |
| Grover, RK; Rao, PN | 1 |
| Chen, LC; Gitlitz, B; Jezior, D; Milne, G; Patel, R; Reckamp, K; Syto, M; Zaknoen, S | 1 |
| Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Bagsby, AL; Freiter, EM; Mandal, PK; McMurray, JS; Robertson, FM | 1 |
| Brekken, RA; Burrows, FJ; Kirane, A; Larsen, JE; Meshaw, KR; Ostapoff, KT; Toombs, JE; Zaknoen, S | 1 |
| Burrows, FJ; Dennis, M; Dohadwala, M; Dubinett, SM; Elashoff, D; Hu, D; Lawhon, T; Lee, JM; Lin, Y; Luo, J; St John, MA; Wang, G; Zaknoen, SL | 1 |
| Braunfeld, J; Brekken, RA; Burrows, FJ; Carbon, JG; Kirane, A; Ostapoff, K; Schwarz, RE; Toombs, JE; Zaknoen, S | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| de Mayolo, JA; Edelman, MJ; Evans, TL; Feliciano, J; Fidler, MJ; Keresztes, R; Medeiros, M; Otterson, G; Rogers, JS; Sanborn, RE; Schneider, BJ; Sequist, LV; Tan, MT; Yang, Y; Zaknoen, SL | 1 |
1 review(s) available for pyrroles and apricoxib
| Article | Year |
|---|---|
Gastroduodenal defense.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Duodenum; Gastric Mucosa; Glucocorticoids; Humans; Intestinal Mucosa; Melatonin; Oxidation-Reduction; Peptides; Phospholipids; Pyrroles; Serotonin; Sulfonamides; Transforming Growth Factor alpha; Trefoil Factor-2 | 2007 |
7 trial(s) available for pyrroles and apricoxib
| Article | Year |
|---|---|
Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Asian People; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Double-Blind Method; Female; Humans; Male; Middle Aged; Mixed Function Oxygenases; Models, Biological; Phenotype; Pyrroles; Sulfonamides | 2006 |
A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa.
Topics: Adult; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Duodenum; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Humans; Intestinal Mucosa; Male; Membrane Proteins; Middle Aged; Naproxen; Pyrroles; Reference Values; Stomach Ulcer; Sulfonamides; Time Factors; United States | 2007 |
A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain.
Topics: Acute Disease; Adolescent; Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Molar, Third; Pain Measurement; Pain, Postoperative; Pyrazoles; Pyrroles; Sulfonamides; Tooth Extraction; Tooth, Impacted; Treatment Outcome | 2007 |
Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.
Topics: Analgesia; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Models, Theoretical; Pain Measurement; Pain, Postoperative; Pyrroles; Sulfonamides; Tooth Extraction; Treatment Outcome | 2008 |
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Prostaglandins; Pyrroles; Quinazolines; Sulfonamides | 2011 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Pemetrexed; Prostaglandins; Pyrroles; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
11 other study(ies) available for pyrroles and apricoxib
| Article | Year |
|---|---|
Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats.
Topics: Animals; Aorta, Thoracic; Carbon Radioisotopes; Celecoxib; Cyclooxygenase 2 Inhibitors; Elastin; Lactones; Male; Protein Binding; Pyrazoles; Pyrroles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Tissue Distribution | 2006 |
Predictive population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor.
Topics: Administration, Oral; Adult; Algorithms; Asian People; Clinical Trials, Phase I as Topic; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Dinoprostone; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Pyrroles; Randomized Controlled Trials as Topic; Software; Sulfonamides; Thromboxane B2; Time Factors; White People | 2007 |
Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice.
Topics: Administration, Oral; Animals; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; ErbB Receptors; Fluorescent Antibody Technique; Gallbladder Neoplasms; Mice; Mice, Transgenic; Pyrroles; Receptor, ErbB-2; Sulfonamides | 2007 |
Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Arthritis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Inflammation; Inhibitory Concentration 50; Pain; Pain Measurement; Pyrroles; Rats; Rats, Inbred Lew; Rats, Wistar; Sulfonamides | 2008 |
CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Drug Screening Assays, Antitumor; Fluorouracil; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Pyrroles; Sulfonamides; Vascular Endothelial Growth Factor A | 2008 |
Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclooxygenase 2 Inhibitors; Humans; Inflammation; Neoplasms; Pain; Pyrroles; Sulfonamides | 2009 |
Translational research in pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Cell Survival; Curcumin; Cyclooxygenase 2 Inhibitors; Epitopes; Focal Adhesion Protein-Tyrosine Kinases; Humans; Mucins; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Pyrroles; Radiation-Sensitizing Agents; Sulfonamides; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2011 |
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
Topics: Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Inflammatory Breast Neoplasms; Pyrroles; Sulfonamides | 2011 |
Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dinoprostone; Epithelial-Mesenchymal Transition; Female; HT29 Cells; Humans; Mice; Mice, Nude; Pyrroles; Sulfonamides; Vascular Endothelial Growth Factor A | 2012 |
Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Head and Neck Neoplasms; Humans; Hydroxyprostaglandin Dehydrogenases; Organic Anion Transporters; Pyrroles; Smoking; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; Up-Regulation; Vimentin | 2012 |
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sulfonamides | 2012 |